Novartis recently announced that its leading drug Cosentyx (secukinumab) improves both signs and symptoms of active ankylosing spondylitis (AS), according to the results of a three-year Phase 3 extension trial called MEASURE 1. The findings were presented recently at the Annual European Congress of Rheumatology (EULAR 2017) in Madrid, Spain.
News
Recent Posts
- Writing about AS has shown me the power of personal stories October 7, 2025
- New biomarker may predict who benefits from AS therapy: Study September 8, 2025
- Filgotinib safe, effective in patients with different forms of axSpA: Trial August 11, 2025
- How physical therapy has improved my life with ankylosing spondylitis July 22, 2025
- Physical activity linked to better health, quality of life in axSpA July 14, 2025